Good morning, everyone, and how are you today? We are doing just fine, thank you. The Pharmalot campus has quieted down now that the shortest person has left for the local schoolhouse and the other short one has left for gainful employment. This leaves us alone with the ever-snoozing official mascots to brew some cups of stimulation — we are stuck on almond toffee so far this week, for those tracking this trend — digging in for another busy session. Toward that end, here are some tidbits for your own journey. Hope today goes well and, as always, please keep in touch …
Chinese regulators approved a new anemia drug from AstraZeneca (AZN) and Fibrogen (FGEN), marking the first time that a medicine from a global pharmaceutical company has received the green light there before any other market, The Wall Street Journal notes. The swift approval, which comes well ahead of any other nation, underscores recent efforts by China to speed its drug approval process and the growing interest among global companies in a market of 1.4 billion people.
About the Author Reprints
J&J is going to buy at a bargain price ‘on the dip.’ Hmmm, will they sell when it rises, so to speak? I would say “vultures” but that would be too complex a word, I fear.